The overall objective of this contract is to identify humoral correlates of protection following H3N2 M2SR vaccination, supporting the clinical development of M2SR as a strategy to induce both…
Active Definitive Contract Awarded Last action
- Contract number
- 75A50125C00005
- Awardee
-
Flugen Inc. UEI M9FHAR3RBML5
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $741,722
Award facts
- Contract value 100% obligated
- $741,722.15 Current and potential, with all options
- Completion date 80% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Madison, WI 53711, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $741,722 |
About this award
The U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (ASPR), awarded a $741,722 firm-fixed-price definitive contract to Flugen Inc. on July 25, 2025, to identify humoral correlates of protection following H3N2 M2SR (monovalent mutant 2 surface reassortant) vaccination. The contract, which carries no set-aside designation and is scheduled for completion by February 28, 2027, will be performed in Madison, Wisconsin, where Flugen maintains its headquarters. The primary objective is to support clinical development of the M2SR vaccination strategy, which aims to provide both seasonal influenza immunity and pre-pandemic protection capabilities.
Flugen Inc., a biopharmaceutical company specializing in intranasal influenza vaccine technologies, brings substantial relevant experience to this research initiative. The company has previously received over $11.8 million in federal grants through the Defense Health Agency's Military Medical Research and Development program, supporting complementary research on H3N2 M2SR vaccine development, manufacturing optimization, and immunogenicity studies. This contract award represents continued federal investment in advancing innovative vaccine platforms that could benefit both military and civilian populations by enhancing pandemic preparedness and seasonal influenza protection strategies.
Description
The overall objective of this contract is to identify humoral correlates of protection following H3N2 M2SR vaccination, supporting the clinical development of M2SR as a strategy to induce both seasonal influenza immunity and pre-pandemic protection a
Quick answers
Who was awarded contract 75A50125C00005?
75A50125C00005 was awarded to Flugen Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on July 25, 2025.
How much is contract 75A50125C00005 worth?
The government has obligated $741,722 on 75A50125C00005.
Was contract 75A50125C00005 competed?
The extent of competition for 75A50125C00005 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award